Proteomic Analysis Reveals Physiological Activities of Aβ Peptide for Alzheimer’s Disease
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25158336 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Xiaorui Ai und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, 122 Luoshi Road, Wuhan 430070, China. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease, Proteomics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the Fundamental Research Funds for the Central Universities, Fundamental Research Funds for the Central Universities.
Themen: Demenz
Abstract (Originalsprache)
With the rapid progress in deciphering the pathogenesis of Alzheimer’s disease (AD), it has been widely accepted that the accumulation of misfolded amyloid β (Aβ) in the brain could cause the neurodegeneration in AD. Although much evidence demonstrates the neurotoxicity of Aβ, the role of Aβ in the nervous system are complex. However, more comprehensive studies are needed to understand the physiological effect of Aβ40 monomers in depth. To explore the physiological mechanism of Aβ, we employed mass spectrometry to investigate the altered proteomic events induced by a lower submicromolar concentration of Aβ. Human neuroblastoma SH-SY5Y cells were exposed to five different concentrations of Aβ1-40 monomers and collected at four time points. The proteomic analysis revealed the time–course behavior of proteins involved in biological processes, such as RNA splicing, nuclear transport and protein localization. Further biological studies indicated that Aβ40 monomers may activate PI3K/AKT signaling to regulate p-Tau, Ezrin and MAP2. These three proteins are associated with dendritic morphogenesis, neuronal polarity, synaptogenesis, axon establishment and axon elongation. Moreover, Aβ40 monomers may regulate their physiological forms by inhibiting the expression of BACE1 and APP via activation of the ERK1/2 pathway. A comprehensive exploration of pathological and physiological mechanisms of Aβ is beneficial for exploring novel treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, 122 Luoshi Road, Wuhan 430070, China.
- Hubei Key Laboratory of Nanomedicine for Neurodegenerative Diseases, Wuhan University of Technology, 122 Luoshi Road, Wuhan 430070, China.
- School of Biological Science & Medical Engineering, Southeast University, No. 2 Sipailou, Nanjing 210096, China.
ORCID-Profile: Jing Li, Chenxi Yang
Förderung
- National Natural Science Foundation of China
- the Fundamental Research Funds for the Central Universities
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Ai, X., Cao, Z., Ma, Z., Liu, Q., Huang, W., Sun, T., Li, J., & Yang, C. (2024). Proteomic Analysis Reveals Physiological Activities of Aβ Peptide for Alzheimer’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158336
Vancouver
Ai X, Cao Z, Ma Z, Liu Q, Huang W, Sun T, et al. Proteomic Analysis Reveals Physiological Activities of Aβ Peptide for Alzheimer’s Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158336
BibTeX
@article{Ai2024,
author = {Ai, Xiaorui and Cao, Zeyu and Ma, Zhaoru and Liu, Qinghuan and Huang, Wei and Sun, Taolei and Li, Jing and Yang, Chenxi},
title = {Proteomic Analysis Reveals Physiological Activities of Aβ Peptide for Alzheimer’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25158336}
}
EUVIMED